Astragaloside-IV induces the differentiation of bone marrow mesenchymal stem cells into osteoblasts through NMUR2-mediated Wnt/β-catenin pathway.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING

Regenerative medicine Pub Date : 2023-06-01 DOI:10.2217/rme-2022-0184

Yujing Cao, Qiuxia Lv, Zhihui Huang, Yang Li

引用次数: 0

Abstract

Aim: Given that astragaloside-IV (As-IV) has the ability to promote osteogenic differentiation, its mechanism is worthy of exploration. Methods: The effect of As-IV on rat tibial defects was examined by histopathological staining and MiR-CT scan. The alkaline phosphatase (ALP) content, osteogenic differentiation-related gene expressions, and mineralized nodule formation in bone marrow mesenchymal stem cells (BMSCs) were detected. Results: As-IV repaired tibial defects of rats. As-IV or neuromedin receptor 2 (NMUR2) overexpression elevated ALP content, mineralized nodules, osteogenic differentiation-related genes, β-catenin and NMUR2 levels, the effects of which were reversed by NMUR2 silencing or Wnt/β-catenin pathway inhibitors. Conclusion: As-IV regulates the Wnt/β-catenin pathway through NMUR2 to promote the repair of tibial defects in rats and the differentiation of BMSCs into osteoblasts.

查看原文本刊更多论文

黄芪甲苷通过nmur2介导的Wnt/β-catenin通路诱导骨髓间充质干细胞向成骨细胞分化。

目的:黄芪甲苷(astragaloside-IV, As-IV)具有促进成骨分化的能力，其机制值得探讨。方法:采用组织病理学染色和MiR-CT扫描检测As-IV对大鼠胫骨缺损的影响。检测骨髓间充质干细胞(BMSCs)碱性磷酸酶(ALP)含量、成骨分化相关基因表达及矿化结节形成。结果:As-IV修复大鼠胫骨缺损。As-IV或神经medin受体2 (NMUR2)过表达升高ALP含量、矿化结节、成骨分化相关基因、β-catenin和NMUR2水平，这些作用可通过NMUR2沉默或Wnt/β-catenin途径抑制剂逆转。结论:As-IV通过NMUR2调控Wnt/β-catenin通路，促进大鼠胫骨缺损修复及BMSCs向成骨细胞分化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.